Skip to main content
Springer Nature Link
Log in

In vitro activity of cefodizime

In vitro Aktivität von Cefodizim

  • Published:
Infection Aims and scope Submit manuscript

Summary

Cefodizime is a bactericidal cephem with the typical broad spectrum activity of an aminothiazolyl cephalosporin, including both gram-positive and gram-negative bacteria: its MIC90 is 0.125 mg/l forStreptococcus pneumoniae, Streptococcus pyogenes and other streptococci; and 0.05 mg/l forHaemophilus spp.,Neisseria meningitidis, Neisseria gonorrhoeae andMoraxella catarrhalis; while β-lactamase positive strains ofM. catarrhalis require 1 mg/l. Less than 1 mg/l is needed forEscherichia coli, Klebsiella spp.,Proteus spp. andShigella spp. The MIC90 is 4 mg/l for methicillin-sensitiveStaphylococcus aureus, Morganella morganii, Providencia spp. and most strains ofSerratia marcescens, Citrobacter spp. andEnterobacter spp.Staphylococcus epidermidis, Enterococcus faecalis and most strains ofPseudomonas spp. andAcinetobacter spp. are considered cefodizime-resistant. Cefodizime is unaffected by plasmid-mediated β-lactamases, but it is hydrolyzed by some chromosomally mediated enzymes, thus resembling other third-generation cephalosporins. Cefodizime has high affinity for PBP 3 and PBP IA and IB (Escherichia coli); inS. aureus it shows the highest affinity for PBP 1.

Zusammenfassung

Cefodizim ist ein bakterizides Cephem mit dem typischen breiten Spektrum eines Aminothiazolyl-Cephalosporins, das sowohl grampositive als auch gramnegative Bakterien einschließt: Die MHK90 beträgt 0,125 mg/l gegenüberStreptococcus pneumoniae, Streptococcus pyogenes und anderen Streptokokken. Sie liegt fürHaemophilus spp.,Neisseria meningitidis, Neisseria gonorrhoeae undMoraxella catarrhalis bei 0,05 mg/l. β-Laktamase positive Stämme vonM. catarrhalis benötigen 1 mg/l. Weniger als 1 mg/l wird fürEscherichia coli, Klebsiella spp.,Proteus spp. undShigella spp. benötigt; die MHK90 beträgt 4 mg/l gegenüber Methicillin-empfindlichen Stämmen vonStaphylococcus aureus, sowie gegenMorganella morganii, Providencia spp., die meisten Stämme vonSerratia marcescens, Citrobacter spp. undEnterobacter spp. Als Cefodizim-resistent sindStaphylococcus epidermidis, Enterococcus faecalis sowie die Mehrzahl der Stämme vonPseudomonas spp. undAcinetobacter spp. anzusehen. Cefodizim wird von plasmidgebundenen β-Laktamasen nicht angegriffen, wie andere Cephalosporine der dritten Generation wird es aber von einigen chromosomal gebundenen β-Laktamasen hydrolysiert. Cefodizim besitzt eine hohe Affinität zu PBP 3 sowie PBP IA und IB (Escherichia coli); beiS. aureus entfaltet es seine höchste Affinität zu PBP 1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brown, J. E., Del Bene, V. E., Collins, C. D. In vitro activity of N-formimidoyl thienamycin, moxalactam and other new beta-lactam agents againstBacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrob. Agents Chemother. 19 (1981) 248–252.

    Google Scholar 

  2. Fu, K. P., Neu, H. C. Beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob. Agents Chemother. 14 (1978) 322–326.

    Google Scholar 

  3. Fu, K. P., Neu, H. C. The comparative β-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J. Antibiot. 32 (1979) 909–914.

    Google Scholar 

  4. Nishida, M., Kamimura, T., Okada, N., Matsumoto, Y., Mine, Y., Murakawa, T., Goto, S., Kuwahara, S. Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics. J. Antibiot. 32 (1979) 1319–1327.

    Google Scholar 

  5. Shannon, K., King, A., Warren, C., Phillips, I. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob. Agents Chemother. 18 (1980) 292–298.

    Google Scholar 

  6. Jones, R. N., Barry, A. L., Thornsberry, C., Wilson, H. W. In vitro antimicrobial activity evaluation of cefodizime (HR 221), a new semisynthetic cephalosporin. Antimicrob. Agents Chemother. 20 (1981) 760–768.

    Google Scholar 

  7. Blumbach, J., Dürckheimer, W., Ehlers, E., Fleischmann, K., Klesel, N., Limbert, M., Mencke, B., Reden, J., Scheunemann, K. H., Schrinner, E., Seibert, G., Wieduwilt, M., Worm, M. Cefodizime, an aminothiazolyl cephalosporin. V. Synthesis and structure-activity relationships in the cefodizime series. J. Antibiot. 40 (1987) 29–42.

    Google Scholar 

  8. Klesel, N., Limbert, M., Seeger, K., Seibert, G., Winkler, I., Schrinner, E. Cefodizime, an aminothiazolyl cephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals. J. Antibiot. 37 (1984) 901–909.

    Google Scholar 

  9. Dagrosa, E. E., Hajdú, P., Malerczyk, V., de Looze, S., Seeger, K., Grötsch, H. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration. Clin. Ther. 10 (1987) 18–31.

    Google Scholar 

  10. Hyodo, A., Higashitani, F., Mitsuhashi, S., Inoue, M. In vitro andin vivo antibacterial activity of cefodizime. Chemotherapy 36 (S-5) (1988) 1–24.

    Google Scholar 

  11. Stille, W., Spieler, S.: Antibacterial activity of cefodizime (HR 221). Proceedings of the 14th International Congress of Chemotherapy, Antimicrobial Section 2. Recent Adv. Chemother. (1985) 923–924.

  12. Limbert, M., Klesel, N., Seeger, K., Seibert, G., Winkler, I., Schrinner, E. Cefodizime, an aminothiazolyl cephalosporin. I.In vitro activity. J. Antibiot. 37 (1984) 892–900.

    Google Scholar 

  13. Kasai, K., Tsuji, A., Miyazaki, S., Goto, S., Fujimoto, K., Masuyoshi, S., Arai, S. In vitro antibacterial activity and β-lactamase stability of cefodizime, a new cephalosporin antibiotic. Jpn. J. Antibiot. 37 (1984) 1294–1305.

    Google Scholar 

  14. Maesen, F. P. V., Davies, B. I., van den Bergh, J. J. A. M., Gubbelmans, H. L. L., Meek, J. C. E., Geraedts, W. H. Cefodizime and cefotaxime in acute exacerbations of chronic bronchitis: a randomized double-blind prospective study in 180 patients. J. Antimicrob. Chemother. 25 (1990) 413–422.

    Google Scholar 

  15. van der Willigen, A. H., Wagenvoort, J. H. T., Schalla, W. O., Knapp, J. S., Boot, J. M., Heeres-Weststrate, P. L., Michel, M. F., van Klingeren, B., Stolz, E. Randomized comparative study of 0.5 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea. Antimicrob. Agents Chemother. 32 (1988) 426–429.

    Google Scholar 

  16. Khan, M. Y., Gruninger, R. P., Nelson, S. M., Obaid, S. R. Comparativein vitro activity of cefodizime, ceftazidime, aztreonam, and other selected antimicrobial agents againstNeisseria gonorrheae. Antimicrob. Agents Chemother. 23 (1983) 477–478.

    Google Scholar 

  17. Pascual, A., Borobio, V., Garcia-Iglesias, M. C., Perea, E. J. Comparativein-vitro activity of cefodizime, cefpirome, carumonam and RU-28965 with other antimicrobials against anaerobes. Antimicrob. Agents Chemother. 19 (1987) 701–703.

    Google Scholar 

  18. Watanabe, K., Sawa, K., Sawamura, H., Yamaoka, K., Aoki, M., Kato, N., Ueno, K. In vitro andin vivo activity of cefodizime against anaerobic bacteria. Chemotherapy 36 (S-5) (1988) 77–94.

    Google Scholar 

  19. Jones, R. N., Wilson, H. W. Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins. Infection 10 (1982) 303–304.

    Google Scholar 

  20. Seibert, G. Studies on the penetration properties of HR 221 through the cell wall of gram-negative bacteria. Hoechst AG, Frankfurt 1982, data on cefodizime submission file.

    Google Scholar 

  21. Scully, B. E., Jules, K., Neu, H. C. In vitro activity and β-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin. Antimicrob. Agents Chemother. 23 (1983) 907–913.

    Google Scholar 

  22. Shah, P. M.: Bactericidal activity of cefodizime under conditions simulating serum pharmacokinetic parameters. Proceedings of the 14th International Congress of Chemotherapy, Antimicrobial Section 2. Recent Adv. Chemother., Kyoto (1985) 935–936.

Download references

Author information

Authors and Affiliations

  1. Zentrum der Inneren Medizin, Labor für Klinische Mikrobiologie, J. W.-Goethe-Universität, Theodor Stern Kai 7–14, W-6000, Frankfurt/Main 70, Germany

    H. Knothe &  P. M. Shah

Authors
  1. H. Knothe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. M. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knothe, H., Shah, P.M. In vitro activity of cefodizime. Infection 20 (Suppl 1), S3–S8 (1992). https://doi.org/10.1007/BF01709942

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01709942

Keywords

Search

Navigation